MedTrace Logo

PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

NCT04477057 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-07-20

No results posted yet for this study

Summary

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.

Conditions

Interventions

DRUG

HS-10241

HS-10241 is a tablet in the form of 100 mg, oral, once daily.

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shun Lu · Shanghai Chest Hospital

  • Shenglin Ma · First People's Hospital of Hangzhou

  • Deguang Mu · Zhejiang Provincial People's Hospital

  • Jianhua Chen · Hunan Cancer Hospital

  • Xiaorong Dong · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  • Xiaoju Zhang · Henan Provincial People's Hospital

  • Xingya Li · The First Affiliated Hospital of Zhengzhou University

  • 7Yubiao Guo · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-21
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04477057 on ClinicalTrials.gov